I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases

Bone Marrow Transplant. 2015 Apr;50(4):607-9. doi: 10.1038/bmt.2014.316. Epub 2015 Jan 26.

Authors

H Yamamoto¹, N Uchida², N Matsuno¹, A Kon¹, A Nishida¹, H Ota¹, T Ikebe¹, N Nakano¹, K Ishiwata¹, H Araoka³, S Takagi¹, M Tsuji¹, Y Asano-Mori¹, G Yamamoto¹, K Izutsu², K Masuoka¹, A Wake¹, A Yoneyama³, S Makino⁴, S Taniguchi²

Affiliations

¹ Department of Hematology, Toranomon Hospital, Tokyo, Japan.
² 1] Department of Hematology, Toranomon Hospital, Tokyo, Japan [2] Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
³ Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan.
⁴ Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan.

PMID: 25621796
DOI: 10.1038/bmt.2014.316

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Busulfan / administration & dosage*
Cord Blood Stem Cell Transplantation
Disease-Free Survival
Female
Hematologic Diseases* / mortality
Hematologic Diseases* / therapy
Humans
Male
Melphalan / administration & dosage*
Middle Aged
Risk Factors
Survival Rate
Transplantation Conditioning*
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives*
Whole-Body Irradiation

Substances

Vidarabine
Busulfan
fludarabine
Melphalan